[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639279":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":48,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"inhalation group","EXPERIMENTAL",null,[13],"Drug: Inhalation Anesthesia",{"label":15,"type":10,"description":11,"interventionNames":16},"intravenous group",[17],"Drug: intravenous anesthesia",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Inhalation Anesthesia","The inhalation group will be maintained with inhaled sevoflurane and a continuous intravenous infusion of remifentanil.",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"intravenous anesthesia","The intravenous group will be maintained with continuous intravenous infusions of both ciprofol and remifentanil.",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Yang Zhao","CONTACT","0086-13802435520","zhaoy47@mail.sysu.edu.cn",[35],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":11},"The Sixth Affiliated Hospital of Sun Yat-sen University","Guangzhou","Guangdong","510655","China","CN",{"type":43,"coordinates":44},"Point",[45,46],113.25,23.11667,{"lat":46,"lon":45},{"type":49,"investigatorFullName":30,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Doctor","100639279","inhalational-versus-intravenous-anesthesia-on-postoperative-lung-injury-in-septic-patients-undergoing-surgery-100639279",false,"NCT07601256","Inhalational Versus Intravenous Anesthesia on Postoperative Lung Injury in Septic Patients Undergoing Surgery","Inhalational Versus Intravenous Anesthesia on Lung Injury After Major Surgery in Patients With Sepsis","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of sepsis according to Sepsis-3.0 (highly suspected or confirmed infection with acute increase in SOFA score ≥ 2).\n3. Scheduled to undergo surgery under general aaesthesia for source control or sepsis-related operative management.\n\nExclusion Criteria:\n\n1. Already intubated prior to entering the operating room.\n2. Chronic home ventilator dependence (e.g., severe chronic obstructive pulmonary disease) before surgery.\n3. Personal or family history of malignant hyperthermia.\n4. Known allergy to ciprofol or sevoflurane.\n5. Known allergy to egg or soy products.\n6. Any contraindication to the planned anaesthetic agents.\n7. Pregnant women.","ALL","18 Years",{"count":61,"type":62},480,"ESTIMATED","INTERVENTIONAL",[65],"NA","This randomized controlled trial will compare the effects of intraoperative inhalational anesthesia versus intravenous anesthesia on postoperative lung injury in septic patients undergoing surgery. The primary goal is to determine if the choice of anesthetic technique influences the incidence or severity of this complication. Participants will be randomly assigned to one of the two anesthetic regimens during surgery. They will receive daily in-hospital assessments for lung injury and other outcomes and will be followed for clinical outcomes until 90 days after the procedure.",[68,69],"Sepsis","Lung Injury","NOT_YET_RECRUITING","2026-05-15",{"date":73,"type":74},"2026-05-22","ACTUAL",{"date":76,"type":62},"2026-08-15",{"date":78,"type":62},"2030-12-30",{"name":5,"class":6},1]